Damora Therapeutics(NASDAQ) DMRA

Damora Therapeutics, Inc. makes medicines for serious blood disorders. Their treatments target bone marrow diseases that affect blood growth. These products help patients manage rare and chronic cancers.

Developing New Blood Treatments

• DMR-001: Monoclonal antibody targeting mutant proteins to block cancer signaling in the bone marrow.
• DMR-002: Antibody designed to trigger the immune system to kill malignant cells.
• DMR-003: Bi-specific antibody intended to recruit immune cells to attack specific cancer-causing mutations.
• Small Molecule Inhibitors: Treatments targeting biological pathways like galectin-3 and LOXL2 implicated in cancer and fibrosis.

Strategic Growth Milestones

• Acquired the original Damora Therapeutics in November 2025 to secure rights to new research programs.
• Exercised exclusive licensing options for product candidates DMR-001 and DMR-002 from Paragon Therapeutics in early 2026.
• Changed the corporate name from Galecto to Damora Therapeutics in March 2026 to reflect its new focus.
• Raised $295,500,000 through a public offering in February 2026 to fund clinical trials and research.
• Relocated the legal jurisdiction of the company to the Cayman Islands in July 2026.

Targeting Root Disease Causes

The company focuses on myeloproliferative neoplasms, which are chronic bone marrow disorders. Its specific targeting of mutated proteins aims to reduce side effects found in non-specific treatments.

Financial Performance Summary

• Research and development expenses were $25.5 million for the quarter ended June 30, 2026, up 1643% year over year.
• General and administrative costs reached $9.5 million for the three-month period ended June 30, 2026, up 383% year over year.
• Net loss was $31.2 million for the quarter ended June 30, 2026, up 807% year over year.
• Cash and cash equivalents totaled $540.5 million as of June 30, 2026.
• Net proceeds from a February 2026 public offering were approximately $295.5 million after fees.

The Evolving Path Ahead

Damora has transitioned from its origins as Galecto to focus on targeted therapies for hematologic disorders. A strong cash position supports its clinical development plans through the second half of 2029.